Sumitomo Dainippon Pharma

Innovation today, healthier tomorrows

Investors Meeting Presentation for Q2 FY2021 (April 1 to September 30, 2021)

October 28, 2021

Hiroshi Nomura, President and CEO
Sumitomo Dainippon Pharma Co., Ltd.

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, targets, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties.

Accordingly, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.

Myovant Sciences Ltd. ("Myovant") is listed on the New York Stock Exchange, and the Group holds approximately 54% of the outstanding shares of Myovant. This material contains information about Myovant, which is based on information disclosed by Myovant. For more information on Myovant, please visit https://www.myovant.com/.

Financial Results for Q2 FY2021

Financial Results for Q2 FY2021 (Core Basis)

Billions of yen

	Q2YTD FY2020 Results	Q2YTD FY2021 Results	Change			FY2021	
			Value	FX impact	%	May 12 forecasts	%
Revenue	261.5	**293.7**	32.2	6.4	12.3	578.0	50.8
Cost of sales	70.7	**76.9**	6.2	3.5	8.7	156.0	49.3
Gross profit	190.8	**216.9**	26.1	3.0	13.7	422.0	51.4
SG&A expenses	93.6	**124.4**	30.9	2.8	33.0	263.0	47.3
R&D expenses	49.2	**45.7**	(3.5)	0.9	(7.1)	95.0	48.1
Other operating income/expenses	(0.0)	**1.2**	1.2	–	–	–	–
Core operating profit	48.0	**47.9**	(0.1)	(0.8)	(0.1)	64.0	74.9
Changes in fair value of contingent consideration (negative number indicates loss)	0.1	**(0.1)**	(0.2)			(1.0)	
Other non-recurring items (negative number indicates loss)	(0.5)	**(0.2)**	0.3			(2.0)	
Operating profit	47.5	**47.6**	0.0		0.1	61.0	78.0
Profit before taxes	43.7	**49.3**	5.6		12.9		
Income tax expenses	13.3	**19.3**	6.0				
Net profit	30.3	**30.0**	(0.4)		(1.2)		
Net profit attributable to owners of the parent	37.3	**36.5**	(0.8)		(2.3)	41.0	88.9

The forecasts are unchanged

■ Progress is almost as expected

(Ref.) Earnings related to Sumitovant

Billions of yen

Q2YTD	FY20	FY21
Revenue	**3.7**	**16.2**
SG&A expenses ＊	15.0	41.4
R&D expenses	13.8	11.5
Core operating profit	**(25.1)**	**(38.9)**
Operating profit	**(25.1)**	**(38.9)**
Net profit	(24.9)	(39.5)
Net profit attributable to owners of the parent	**(18.0)**	**(33.0)**

The figures include intra-group transaction

＊Include amortization of patent rights

FX rates:
Q2FY2020 Results : 1US$ = ¥106.9, 1RMB = ¥15.3
Q2FY2021 Results : 1US$ = ¥109.8, 1RMB = ¥17.0
FY2021 forecasts : 1US$ = ¥110.0, 1RMB = ¥16.5

Financial Results for Q2 FY2021

Revenue of Major Products in Japan

Billions of yen

	Q2 YTD FY2020 Results	Q2 YTD FY2021 Results	Change		FY2021	
			Value	%	May 12 forecasts	%
Equa®/EquMet®	20.4	**19.3**	(1.2)	(5.7)	37.4	51.5
Trulicity® *	16.8	**17.2**	0.4	2.3	38.2	45.0
TRERIEF®	8.3	**8.4**	0.2	1.9	17.9	47.1
REPLAGAL®	6.9	**7.1**	0.2	2.9	13.8	51.5
METGLUCO®	4.7	**4.1**	(0.6)	(11.8)	6.9	60.0
LATUDA®	0.9	**3.0**	2.1	243.6	6.7	44.9
LONASEN® Tape	0.6	**1.0**	0.4	71.9	2.5	38.2
AMLODIN®	3.3	**2.9**	(0.4)	(13.3)	5.0	57.8
AG products	3.8	**4.8**	1.1	28.3	10.1	47.7
Others	11.7	**8.8**	(2.9)	(25.1)	11.5	76.4
Total	77.3	**76.6**	(0.8)	(1.0)	150.0	51.1

Note: Sales of each product are shown by invoice price (* Trulicity® is shown by NHI price)

- Progress is almost as expected in the segment total
- Decrease in Equa® /Eqmet® is attributed to NHI price revision
- LATUDA® showing steady growth
- Others include TWYMEEG® launched on September 16
- NHI price revision affected ¥3.5B on Japan segment total

Revenue of Major Products in North America & China

	Q2 YTD FY2020 Resuts	Q2 YTD FY2021 Results	Change	Q2 YTD FY2020 Resuts	Q2 YTD FY2021 Results	Change			FY2021		
						Value	FX impact	%	May 12 forecasts		Yen-basis %
North America	Million $			Billions of yen					Million $	Billion yen	
LATUDA®	978	920	(58)	104.6	101.0	(3.6)	2.7	(3.4)	2,004	220.4	45.8
APTIOM®	125	124	(1)	13.4	13.6	0.3	0.4	2.0	249	27.4	49.7
BROVANA®	141	83	(59)	15.1	9.1	(6.0)	0.2	(39.9)	106	11.7	77.6
KYNMOBI®	1	3	3	0.1	0.3	0.3	0.0	166.4	28	3.1	10.9
ORGOVYX®	—	29	29	—	3.2	3.2	0.1	—	792	87.1	58.3
MYFEMBREE®	—	3	3	—	0.4	0.4	0.0	—			
GEMTESA®	—	19	19	—	2.1	2.1	0.1	—			
Others	106	411	305	11.3	45.1	33.8	1.2	299.0			
Total	1,351	1,592	241	144.5	174.9	30.3	4.6	21.0	3,179	349.7	50.0
China	Million RMB			Billions of yen					Million RMB	Billion yen	
MEROPEN®	649	850	201	9.9	14.4	4.5	1.5	45.4	1,364	22.5	64.0
Others	157	217	61	2.4	3.7	1.3	0.4	56.3	442	7.3	51.2
Total	806	1,067	262	12.3	18.1	5.8	1.8	47.5	1,806	29.8	60.9

FX rates:
Q2FY2020 Results : 1US$ = ¥106.9, 1RMB = ¥15.3
Q2FY2021 Results : 1US$ = ¥109,8, 1RMB = ¥17.0
FY2021 forecasts : 1US$ = ¥110.0, 1RMB = ¥16.5

- **North America segment**
  Revenue increased y-o-y, progress in line with full-year forecast
- LATUDA® decreased due largely to down-stream inventory destocking
- BROVANA® decreased due to loss of exclusivity in June
- 3 new products related to Sumitovant are on track
- Revenue from the alliance with Otsuka $270M (¥29.7B) is recorded in “Others”
- **China segment**
  Increased sales by recovering from the effect of COVID-19
  Progress is higher than forecast

Covered Lives and Cumulative Number of Patients/Monthly TRx of ORGOVYX®, MYFEMBREE® and GEMTESA®

Sumitomo Dainippon Pharma

■ Trends in gaining of covered lives and cumulative number of patients/monthly TRx in the U.S.

（As of Oct. 2021, ratio of gaining of covered lives to total number of Commercial/ Medicare Part D lives, including Pre-review Coverage）

ORGOVYX®

（Launched in January 2021）



MYFEMBREE®

（Launched in June 2021）



GEMTESA®

（Launched in April 2021）



Left axis: % (: Commercial lives, : Medicare Part D lives), Right axis: people (:Cumulative number of patients, :Number of monthly TRx)

MYFEMBREE®'s main coverage is Commercial lives

The total number of Commercial lives (including exchange) are approx. 177.8 million and Medicare Part D lives are approx. 46.2 million in the U.S.

Segment Information (Core Basis)

Billions of yen

		Pharmaceuticals Business					Other Business	Total
		Japan	North America	China	Other Regions	Subtotal		
Q2 YTD FY2021 Results	Revenue (Sales to customers)	76.6	174.9	18.1	4.6	274.2	19.6	293.7
	Cost of sales	41.3	15.2	3.1	2.2	61.8	15.1	76.9
	Gross profit	35.3	159.6	15.0	2.4	212.4	4.5	216.9
	SG&A expenses	25.5	89.4	5.4	1.5	121.9	2.6	124.4
	Core segment profit	9.8	70.2	9.6	0.9	90.5	1.9	92.4
	R&D expenses					45.3	0.4	45.7
	Core operating profit					46.4	1.5	47.9
Q2 YTD FY2020 Results	Revenue (Sales to customers)	77.3	144.5	12.3	9.3	243.5	18.0	261.5
	Cost of sales	40.2	11.5	2.2	3.2	57.1	13.6	70.7
	Gross profit	37.2	133.0	10.1	6.2	186.4	4.4	190.8
	SG&A expenses	23.8	62.2	3.8	1.3	91.1	2.5	93.6
	Core segment profit	13.3	70.8	6.3	4.9	95.3	1.9	97.2
	R&D expenses					48.8	0.4	49.2
	Core operating profit					46.5	1.5	48.0
Change	Revenue (Sales to customers)	(0.8)	30.3	5.8	(4.8)	30.7	1.6	32.2
	SG&A expenses	1.7	27.2	1.6	0.3	30.8	0.1	30.9
	Core segment profit	(3.5)	(0.6)	3.3	(4.0)	(4.8)	0.0	(4.8)
	R&D expenses					(3.5)	0.0	(3.5)
	Core operating profit					(0.1)	0.0	(0.1)

- **Japan:** Lower profit due to declined gross profit and increased expenses
- **North America:** Lower profit mainly due to incremental costs of Sumitovant despite lump-sum revenue from the alliance
- **China:** Profit increased mainly due to higher revenue
- **Other Regions:** Lower profit mainly due to decrease in export

Alliance with Otsuka Pharmaceutical

Alliance with Otsuka Pharmaceutical

Outline of Agreement (1)

Outline	Enter into a collaboration and license agreement for joint development and commercialization with Otsuka Pharmaceutical Co., Ltd. (September 2021)	
Compounds	SEP-363856（generic name: ulotaront） SEP-4199 SEP-378614 SEP-380135	
Sales territory	**Region**	**Sales Entity**
	United States, Canada, Japan, China, Taiwan, Singapore, Thailand, Vietnam, and Malaysia	Sumitomo Dainippon Pharma Group will record sales Sumitomo Dainippon Pharma Group and Otsuka plan to co-promote jointly
	41 other countries and regions including countries in Europe	Otsuka will record sales
	Other regions	To be discussed
Consideration	Upfront payment $270 million Development milestones $620 million (potentially more depending on the number of additional indications obtained) Sales milestones Potentially	
Accounting treatment	Upfront payment is posted as revenue on the closing date, and lump sum payments will be posted as revenue at the time of meeting each milestone	

Alliance with Otsuka Pharmaceutical

Outline of Agreement (2)

Sumitomo Dainippon Pharma

Worldwide Joint Development for Four Candidate Compounds
in Psychiatry & Neurology Area

Sumitomo Dainippon Pharma

sunovion

Otsuka

- The Joint Development Committee consisting of the three parties decides on the strategy, direction and roles of joint development
- Responsibility for conducting clinical studies will be decided for each indication

Compounds	Proposed indication	Development status	Future plans
ulotaront (SEP-363856)	Schizophrenia	U.S.: Phase 3 studies in progress Japan, China: Phase 2/3 study in progress	U.S.: Expecting topline results of Phase 3 studies in 2022 Aim to launch in FY2023 Japan, Asia: Aim to launch in the second half of the 2020s
	The second and third indications	-	Under consideration including conducting studies for the second and third indications in parallel
SEP-4199	Bipolar I depression	U.S.: Started Phase 3 study Japan: Preparing to join this Phase 3 study	U.S., Japan: Aim to launch in the second half of the 2020s
SEP-378614	To be determined	U.S.: Phase 1 study in progress	Under consideration
SEP-380135	To be determined	U.S.: Phase 1 study in progress	Under consideration

Research and Development

Research and Development

Development Pipeline (as of October 27, 2021)

Sumitomo Dainippon Pharma

: Psychiatry & Neurology : Oncology : Regenerative medicine / Cell therapy : Others : Frontier business Revisions since the announcement of July 2021 are shown in red

Area	Phase 1		Phase 2	Phase 3	NDA submitted
Japan	**DSP-1181** (Obsessive compulsive disorder) **DSP-9632P** (Levodopa-induced dyskinesia in Parkinson's disease)	**DSP-0390** (Solid tumors) **TP-3654** (Hematologic malignancies)	**SEP-4199** (Bipolar I depression) **EPI-589** (ALS/Investigator-initiated study) **Allo iPS cell-derived products** (Parkinson's disease/ Investigator-initiated study)	**ulotaront (SEP-363856)** (Schizophrenia) **DSP-7888** (Glioblastoma) **SMC-01** (Mobile App for management of type 2 diabetic patients)	
U.S.	**DSP-6745** (Parkinson's disease psychosis) **SEP-378608** (Bipolar disorder) **DSP-3905** (Neuropathic pain) **SEP-378614** (To be determined) **SEP-380135** (To be determined) **DSP-0038** (Alzheimer's disease psychosis)	**guretolimod (DSP-0509)** (Solid tumors) **itacnosertib (TP-0184)** (Hematologic malignancies) **TP-1287** (Solid tumors) **TP-3654** (Hematologic malignancies) **TP-1454** (Solid tumors) **DSP-0390** (Solid tumors) **DSP-5336** (Hematologic malignancies)	**EPI-589** (Parkinson's disease/ALS) **ulotaront (SEP-363856)** (Parkinson's disease psychosis) **dubermatinib (TP-0903)** (AML/Research group-initiated study) **rodatristat ethyl** (Pulmonary arterial hypertension) **URO-902** (Overactive bladder)	**ulotaront (SEP-363856)** (Schizophrenia) **SEP-4199** (Bipolar I depression) **DSP-7888** (Glioblastoma) **GEMTESA® (vibegron)** (New indication: OAB in men with BPH)	**MYFEMBREE® (relugolix)** (New indication: Endometriosis)
China				**LATUDA®** (New indication: Bipolar I depression) **ulotaront (SEP-363856)** (Schizophrenia)	**lefamulin** (Bacterial community-acquired pneumonia)
Europe					**relugolix** (Prostate cancer)

Clinical Development Status (Major Changes since July 29, 2021)

- **SEP-4199**
  U.S. : Started Phase 3 study for bipolar I depression (Japan will join this Phase 3 study)
- **EPI-589**
  Japan : Started Phase 2 study (Investigator-initiated study) for amyotrophic lateral sclerosis (ALS)
- **DSP-9632P**
  Japan : Started Phase 1 study for levodopa-induced dyskinesia in Parkinson's disease
- **TP-3654**
  Japan : Started Phase 1 study for hematologic malignancies
- **RETHYMIC® (RVT-802)**
  U.S. : Approved for pediatric congenital athymia in October 2021 and planning to launch in November 2021
- **MYFEMBREE® (relugolix combination tablet)**
  U.S. : Accepted for sNDA for endometriosis in September 2021
  - PDUFA date: May 6, 2022
- **Lefamulin**
  China : Submitted NDA bacterial community-acquired pneumonia in October 2021

SEP-4199 Phase 3 Study Overview

- Sponsor : Sunovion (global study including the U.S. and Japan)
- Target indication : Bipolar I depression
- Study design :



Study 301: Primary endpoint

- Change from Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale （MADRS） total score

Study 301: Secondary endpoint

- Change from Baseline to Week 6 in Clinical Global Impression-Bipolar Version-Severity of Illness （CGI-BP-S) depression score

Safety/Tolerability

- The incidence of overall Adverse Events (AEs), serious AEs, and discontinuation due to AEs, etc.

Appendix

＜Contents＞

Financial Results for Q2 FY2021 (Full Basis)

Billions of yen

	Q2 YTD FY2020 Results	Q2 YTD FY2021 Results	Change	%
Revenue	261.5	293.7	32.2	12.3
Cost of sales	70.7	76.9	6.2	8.7
Gross profit	190.8	216.9	26.1	13.7
SG&A expenses	94.2	124.7	30.5	32.4
R&D expenses	49.2	45.7	(3.5)	(7.1)
Other operating income and expenses	0.1	1.1	1.0	
Operating profit	47.5	47.6	0.0	0.1
Finance income and costs	(3.9)	1.7	5.6	
Profit before taxes	43.7	49.3	5.6	12.9
Income tax expenses	13.3	19.3	6.0	
Net profit	30.3	30.0	(0.4)	(1.2)
Net profit attributable to owners of the parent	37.3	36.5	(0.8)	(2.3)

Financial Position

Billions of yen

B / S	As of March 2021	As of Sep. 2021	Change
Assets	1,308.1	1,267.4	(40.7)
Goodwill / Intangible assets	559.9	557.2	(2.7)
Other financial assets (Non-current)	193.0	154.6	(38.5)
Trade and other receivables	135.9	176.0	40.1
Other financial assets (Current)	29.5	13.4	(16.1)
Cash and deposit / Short-term loan receivable	193.7	156.5	(37.2)
Liabilities	659.9	618.7	(41.2)
Bonds and borrowings	273.8	270.4	(3.4)
Trade and other payables	64.6	48.2	(16.4)
Provisions	99.9	95.2	(4.6)
Equity	648.2	648.7	0.5
Attributable to owners of the parent	580.6	582.3	1.7
Ratio of equity attributable to owners of the parent to total assets	44.4%	45.9%	

C / F	Q2YTD FY2020	Q2YTD FY2021	Change
Operating CF	26.1	(28.2)	(54.3)
Investment CF	19.4	3.6	(15.7)
Financial CF	(9.8)	(13.2)	(3.5)
Cash and cash equivalents	134.7	156.5	21.8
(Operating funds)	134.7	168.6	

Decrease by change in value of securities

Increase by posting lump-sum revenue from the alliance

Decrease by collection of short-term loan

Increase in Trade and other receivables mainly due to posting lump-sum revenue from the alliance
Decrease in Trade and other payables

Increase in purchase of investments

Appendix (Research and Development)

Main Event / Target for FY2021 (as of October 27, 2021)

✓ Completed action / target Revisions since the announcement of July 2021 are shown in red

Psychiatry & Neurology	☐ ulotaront (SEP-363856) : ☐ Start clinical program for the development (global study) of new indication ☐ Advance Phase 3 study in the U.S. and Phase 2/3 study in Japan and China for schizophrenia ☑ SEP-4199: Start Phase 3 study for Bipolar I depression
Oncology	☐ DSP-7888 : Advance global Phase 3 study for glioblastoma
Regenerative medicine / Cell therapy	☑ RVT-802 : Obtain approval for pediatric congenital athymia in the U.S. ☐ Allogeneic iPS cell-derived products（AMD: age-related macular degeneration) : Start clinical study ☐ Allogeneic iPS cell-derived products（Parkinson's disease) : Complete transplant in investigator-initiated study
Infectious Diseases	☐ Antimicrobial resistance (AMR), universal influenza vaccine, malaria vaccines : Promote joint research and development projects
Others	☐ relugolix : (U.S.) ☑ Obtain approval for uterine fibroids ☑ Submit NDA for endometriosis (Europe) ☑ Obtain approval for uterine fibroids ☐ Submit MAA for endometriosis ☑ imeglimin : Obtain approval for type 2 diabetes in Japan
Frontier	☐ Promote the current themes (Type 2 diabetes management app, Neurorehabilitation device for hand/fingers, Digital device for relieving BPSD, Automated blood collection/Stabilization device, VR contents for Social Anxiety Disorder, and internal themes, etc.) and development of new themes

Appendix (Research and Development)

Product Launch Target (as of October 27, 2021)

Revisions since the announcement of July 2021 are shown in red

RETHYMIC®
(Pediatric congenital athymia)
Approved in Oct. 2021
Plan to launch in Nov. 2021

TWYMEEG®
(Type 2 diabetes)
Launched in Sep. 2021

MYFEMBREE®
(Uterine fibroids)
Launched in June 2021

GEMTESA®
(OAB)
Launched in April 2021

MYFEMBREE®
(New indication: Endometriosis)
PDUFA date May 2022

ulotaront (SEP-363856)
(Schizophrenia)

Allo iPS cell-derived products
(Parkinson's disease) *

DSP-7888
(Glioblastoma)

LATUDA®
(New indication: Bipolar I depression)

lefamulin
(Bacterial community -acquired pneumonia)

Allo iPS cell-derived products
(AMD) *

FY2021	FY2022	FY2023	FY2024	FY2025

Planning to launch multiple frontier business items after FY2022 (separately listed)

: Psychiatry & Neurology
: Regenerative medicine / cell therapy
: Frontier business
: Oncology
: Others

* Launch schedule is based on our goal pending agreement with partners

Appendix (Research and Development)

Product Launch Target (Frontier business) (as of October 27, 2021)

FY2022	FY2023	FY2024	FY2025	FY2026	FY2027 onward
Type 2 diabetes management app	Automated blood collection/ Stabilization device		Violet Light (Depression)		Digital medical device for depression diagnosis
Digital device for relieving BPSD *1	Smart glasses for hard of hearing people	Violet Light (Depression)	Violet Light (Dementia)		Digital device for relieving BPSD
VR contents for Social Anxiety Disorder *2	Wearable EEG meter	Violet Light (Dementia)	Neurorehabilitation device for hand/fingers	VR contents for Social Anxiety Disorder	VR business (Disease area expansion)

*1 Sales by partners

*2 Sales by partners, and planning to expand target symptoms continuously

: Medical device

: Non-medical device

The project description varies with the product (device sales, solution business, royalties, etc.)

Appendix (Research and Development)

Regenerative Medicine/Cell Therapy Business Plan (as of October 27, 2021)

Revisions since the announcement of July 2021 are shown in red

Proposed indication, etc.	Partnering	Region (planned)	Cell type	status	
Pediatric congenital athymia (RETHYMIC®)	Duke University	Global	Cultured thymus tissue	**Approved in October 2021 (U.S.)**	
AMD (age-related macular degeneration)	Healios RIKEN	Global	Allo iPS cell-derived retinal pigment epithelium	**In progress: clinical research Preparing to start clinical study (Japan)**	**Aim to start clinical study in FY2021**
Parkinson's disease (Designated as a "SAKIGAKE")	Kyoto University CiRA	Global	Allo iPS cell-derived dopamine neural progenitor	**In progress: investigator-initiated study (Phase 1 / 2 study) (Japan)**	**Aim to launch in FY2023 ***
Retinitis pigmentosa	RIKEN	Global	Allo iPS cell-derived photoreceptor (3D)	**In progress: clinical research**	
Spinal cord injury	Keio University Osaka National Hospital	Global	Allo iPS cell-derived neural progenitor	**In progress: clinical research**	
Kidney failure	Jikei University Bios PorMedTec	Japan, North America	Auto/ Allo iPS cell-based induced nephron progenitor cells (organ)	**In progress: pre-clinical study**	

* Launch schedule is based on our goal pending agreement with partners

New Chemical Entity: DSP-9632P

- ✓ Target indication：Levodopa-induced dyskinesia in Parkinson's disease
- ✓ Origin：In-house
- ✓ Mechanism of action：Suppression of excessive release of levodopa-derived dopamine
- ✓ Stage：Phase 1 (Japan)
- ✓ Expected profile：
  - ➢ DSP-9632P is a serotonin 5-HT_{1A} receptor partial agonist, and it is expected to exert an effect on dyskinesia expressed after administration of levodopa by suppressing the excessive release of levodopa-derived dopamine
  - ➢ The transdermal formulation of DSP-9632P could present continuous blood drug concentration, and could potentially have a stable effect on levodopa-induced dyskinesia in Parkinson's disease



Appendix (Research and Development)

Development Status of Relugolix and GEMTESA® (Vibegron)

Revisions since the announcement of July 2021 are shown in red

■ Development status of relugolix

Oncology area (monotherapy) U.S. : ORGOVYX®	Prostate cancer U.S. : Launched in January 2021 Europe : MAA submitted in March 2021 ➢ (North America) Myovant entered into a collaborative development and commercialization agreement with Pfizer Inc. in December 2020 ➢ (Outside North America, excluding certain Asia) Pfizer Inc. declined its option for commercialization, Myovant is currently assessing partnership opportunities
Women's health area (combination tablet) U.S. : MYFEMBREE® Europe : RYEQO®	Uterine fibroids U.S. : Approved in May 2021 and launched in June 2021 Europe : Approved in July 2021 and launched in seven countries by Gedeon Richter Plc. Endometriosis U.S. : sNDA submitted by Myovant in July 2021, PDUFA date May 6, 2022 Europe : Gedeon Richter Plc. plans to submit in 2021 ➢ (North America) Myovant entered into a collaborative development and commercialization agreement with Pfizer Inc. in December 2020 ➢ (Europe, Russia etc.) Myovant entered into a collaborative development and commercialization agreement with Gedeon Richter Plc. in March 2020

■ Development status of GEMTESA® (vibegron)

Overactive bladder (OAB)	U.S. : Launched in April 2021
OAB in men with BPH	U.S. : Phase 3 study stage and expecting topline results in FY2022

Sumitomo Dainippon Pharma

Innovation today, healthier tomorrows